349 related articles for article (PubMed ID: 32629125)
1. Definition and Management of Patients With Primary Biliary Cholangitis and an Incomplete Response to Therapy.
Montano-Loza AJ; Corpechot C
Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2241-2251.e1. PubMed ID: 32629125
[TBL] [Abstract][Full Text] [Related]
2. The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study.
Jones DEJ; Wetten A; Barron-Millar B; Ogle L; Mells G; Flack S; Sandford R; Kirby J; Palmer J; Brotherston S; Jopson L; Brain J; Smith GR; Rushton S; Jones R; Rushbrook S; Thorburn D; Ryder SD; Hirschfield G; ; Dyson JK
EBioMedicine; 2022 Jun; 80():104068. PubMed ID: 35609437
[TBL] [Abstract][Full Text] [Related]
3. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
Hirschfield GM; Dyson JK; Alexander GJM; Chapman MH; Collier J; Hübscher S; Patanwala I; Pereira SP; Thain C; Thorburn D; Tiniakos D; Walmsley M; Webster G; Jones DEJ
Gut; 2018 Sep; 67(9):1568-1594. PubMed ID: 29593060
[TBL] [Abstract][Full Text] [Related]
4. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and Treatment of Primary Biliary Cholangitis].
Kim KA
Korean J Gastroenterol; 2023 Feb; 81(2):86-90. PubMed ID: 36824036
[TBL] [Abstract][Full Text] [Related]
6. Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis.
Gazda J; Drazilova S; Gazda M; Janicko M; Koky T; Macej M; Carbone M; Jarcuska P
Dig Liver Dis; 2023 Oct; 55(10):1318-1327. PubMed ID: 36593158
[TBL] [Abstract][Full Text] [Related]
7. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
8. Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study.
Papastergiou V; Tsochatzis EA; Rodriguez-Peralvarez M; Thalassinos E; Pieri G; Manousou P; Germani G; Rigamonti C; Arvaniti V; Karatapanis S; Burroughs AK
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1354-64. PubMed ID: 24117847
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
[TBL] [Abstract][Full Text] [Related]
10. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
Soret PA; Lam L; Carrat F; Smets L; Berg T; Carbone M; Invernizzi P; Leroy V; Trivedi P; Cazzagon N; Weiler-Normann C; Alric L; Rosa-Hezode I; Heurgué A; Cervoni JP; Dumortier J; Potier P; Roux O; Silvain C; Bureau C; Anty R; Larrey D; Levy C; Pares A; Schramm C; Nevens F; Chazouillères O; Corpechot C
Aliment Pharmacol Ther; 2021 May; 53(10):1138-1146. PubMed ID: 33764590
[TBL] [Abstract][Full Text] [Related]
11. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
[TBL] [Abstract][Full Text] [Related]
12. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
13. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.
Örnolfsson KT; Lund SH; Olafsson S; Bergmann OM; Björnsson ES
Scand J Gastroenterol; 2019 May; 54(5):609-616. PubMed ID: 31074667
[No Abstract] [Full Text] [Related]
14. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
Yuan Z; Jia G; Han Y
Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
[TBL] [Abstract][Full Text] [Related]
15. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
Cheung AC; Lapointe-Shaw L; Kowgier M; Meza-Cardona J; Hirschfield GM; Janssen HL; Feld JJ
Aliment Pharmacol Ther; 2016 Jan; 43(2):283-93. PubMed ID: 26559762
[TBL] [Abstract][Full Text] [Related]
16. Primary biliary cholangitis: treatment.
Cazzagon N; Floreani A
Curr Opin Gastroenterol; 2021 Mar; 37(2):99-104. PubMed ID: 33492001
[TBL] [Abstract][Full Text] [Related]
17. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
[TBL] [Abstract][Full Text] [Related]
18. Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
Parés A
Dig Dis; 2015; 33 Suppl 2():125-33. PubMed ID: 26642350
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice.
Gómez E; Montero JL; Molina E; García-Buey L; Casado M; Fuentes J; Simón MA; Díaz-González A; Jorquera F; Morillas RM; Presa J; Berenguer M; Conde MI; Olveira A; Macedo G; Garrido I; Hernández-Guerra M; Olivas I; Rodríguez-Tajes S; Londoño M; Sousa JM; Ampuero J; Romero-González E; González-Padilla S; Escudero-García D; Carvalho A; Santos A; Gutiérrez ML; Pérez-Fernández E; Aburruza L; Uriz J; Gomes D; Santos L; Martínez-González J; Albillos A; Fernández-Rodríguez CM
Aliment Pharmacol Ther; 2024 Jun; 59(12):1604-1615. PubMed ID: 38690746
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.
Ding D; Guo G; Liu Y; Zheng L; Jia G; Deng J; Sun R; Wang X; Guo C; Shang Y; Han Y
Hepatol Commun; 2022 Dec; 6(12):3487-3495. PubMed ID: 36213941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
